-
Novartis AG (NYSE:NVS; SIX:NOVN) said once-daily QVA149 met the primary endpoint of improving patient self-reported shortness of breath during daily activities as measured by Transition Dyspnea Index (TDI) scores from …
Published on 5/21/2013
-
Aduro BioTech Inc. (Berkeley, Calif.) stopped early a Phase II trial evaluating CRS-207 plus GVAX Pancreas cancer vaccine and cyclophosphamide to treat pancreatic cancer after the combination met the primary endpoint of…
Published on 5/20/2013
-
H. Lundbeck A/S (CSE:LUN) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) presented additional data on Monday showing that some doses of Brintellix vortioxetine significantly improved depression rating scores …
Published on 5/20/2013
-
Pfizer Inc. (NYSE:PFE) said it discontinued the Phase III B1931008 trial evaluating inotuzumab ozogamicin to treat relapsed or refractory CD22-positive aggressive non-Hodgkin's lymphoma. The move came after an interim …
Published on 5/20/2013
-
XenoPort Inc. (NASDAQ:XNPT) fell $1.03 (15%) to $5.72 on Monday after discontinuing development of arbaclofen placarbil based on top-line data showing that twice-daily doses of the product missed the co-primary …
Published on 5/20/2013
-
Novo Nordisk A/S (CSE:NVO; NYSE:NVO) reported data on Friday from the 74-patient Phase III paradigm 2 trial evaluating N9-GP -- a glyco-pegylated derivative of recombinant human Factor IX -- to treat and prevent …
Published on 5/17/2013
-
ThromboGenics N.V. (Euronext:THR) disclosed in a business update for the period ending April 30 that ocriplasmin missed the primary endpoint in the Phase IIa MIVI-5 trial to treat focal vitreomacular adhesion (VMA) …
Published on 5/17/2013
-
Halozyme Therapeutics Inc. (NASDAQ:HALO) gained $1.24 (18%) to $7.98 on Thursday after reporting data from 24 evaluable patients in the open-label, dose-escalation Phase Ib portion of a Phase I/II trial to treat …
Published on 5/16/2013
-
Helsinn Healthcare S.A. (Pazzallo-Lugano, Switzerland) said a single dose of its oral Netu-palo-FDC (NEPA) plus dexamethasone was superior to a single dose of oral palonosetron plus dexamethasone on the primary endpoint…
Published on 5/16/2013
-
Oncothyreon Inc. (NASDAQ:ONTY) fell $0.64 (25%) to $1.97 on Thursday after reporting data from two Phase II trials of once-daily oral PX-866 to treat recurrent glioblastoma multiforme (GBM) and recurrent or metastatic …
Published on 5/16/2013
-
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said once-daily 25 and 50 mg oral fasiglifam each met the primary endpoint of reducing HbA1c from baseline to week 24 vs. placebo in the Phase III CCT-003 trial to treat Type …
Published on 5/16/2013
-
Bristol-Myers Squibb Co. (NYSE:BMY) reported interim data late Wednesday from 52 evaluable patients showing that concurrent dosing with the pharma's Yervoy ipilimumab plus nivolumab led to an objective response rate (…
Published on 5/15/2013
-
The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said IV MPDL3280A once every three weeks led to an objective response rate (ORR) of 21% in 140 patients with locally advanced or metastatic solid tumors whose …
Published on 5/15/2013
-
Bharat Biotech International Ltd. (Hyderabad, India) said oral Rotavac significantly reduced severe rotavirus diarrhea by 56% during the first year of life vs. placebo in an Indian Phase III trial to prevent rotavirus …
Published on 5/14/2013
-
Eli Lilly and Co. (NYSE:LLY) discontinued development of enzastaurin (LY31765) after top-line data showed daily enzastaurin missed the primary endpoint of improving disease-free survival (DFS) vs. placebo in the Phase …
Published on 5/10/2013
-
Oncothyreon Inc. (NASDAQ:ONTY) disclosed in its 1Q13 earnings late Thursday that once-daily oral PX-866 plus docetaxel missed the primary endpoint of improving progression-free survival (PFS) vs. docetaxel alone in a …
Published on 5/10/2013
-
Italian researchers reported that a once-daily 1 g dose of N-3 polyunsaturated fatty acids missed the primary endpoint in a Phase III trial in 12,513 patients with multiple cardiovascular risk factors or atherosclerotic…
Published on 5/8/2013
-
Baxter International Inc. (NYSE:BAX) said both 200 and 400 mg/kg doses of IV Gammagard Liquid 10% given every two weeks missed the co-primary endpoints in the 390-patient Phase III GAP trial (Study 160701) to treat mild…
Published on 5/7/2013
-
Celgene Corp. (NASDAQ:CELG) reported additional data for apremilast on Monday and also announced revenue guidance for the oral phosphodiesterase-4 (PDE-4) inhibitor. In the Phase III PALACE-4 trial to treat psoriatic …
Published on 5/6/2013
-
Gilead Sciences Inc. (NASDAQ:GILD) reported interim data from the Phase II LONESTAR trial evaluating a once-daily, oral fixed-dose combination of sofosbuvir plus ledipasvir (GS-5885) to treat chronic HCV genotype 1 …
Published on 5/2/2013
-
Almirall S.A. (Madrid:ALM) and partner Forest Laboratories Inc. (NYSE:FRX) said twice-daily 400/12 ug aclidinium bromide/formoterol delivered via Almirall's Genuair inhaler met the co-primary endpoints in the Phase III …
Published on 5/1/2013
-
Seaside Therapeutics Inc. (Cambridge, Mass.) said oral STX209 for 12 weeks missed the primary endpoint vs. placebo in the Phase IIb Study 209AS208 to treat autism spectrum disorders (ASD). Specifically, STX209 missed …
Published on 5/1/2013
-
NIH's National Institute of Allergy and Infectious Diseases (NIAID) discontinued the Phase IIb HVTN 505 trial to prevent HIV infection after an interim analysis showed a lack of efficacy of the vaccine regimen in the …
Published on 4/25/2013
-
Sanofi (Euronext:SAN; NYSE:SNY) said once-daily oral Aubagio teriflunomide met the primary endpoint vs. placebo in the Phase III TOPIC trial to prevent or delay conversion of clinically isolated syndrome (CIS) to …
Published on 4/25/2013
-
Bristol-Myers Squibb Co. (NYSE:BMY) reported data on Tuesday from a Phase IIa trial evaluating an oral regimen of twice-daily asunaprevir, once-daily daclatasvir and twice-daily BMS-791325 to treat HCV genotype 1 …
Published on 4/23/2013